Navigation Links
Arpida to Restructure and Focus on Key Projects
Date:11/27/2008

REINACH, Switzerland, November 27 /PRNewswire-FirstCall/ -- Arpida announced today that it is refocusing all projects and priorities around the key strategic asset Iclaprim. The company says this is to be seen as a consequence of the negative recommendation of the U.S. Food and Drug Administration (FDA) advisory board on 20 November 2008 regarding the approval of Iclaprim in the U.S.

In the context of the FDA advisory board's recommendation the Arpida board intends to put the company back on a firm footing through cutting costs considerably. To achieve this, the company views the reduction of the workforce by up to 60 employees as inevitable. A consultation process with all employees has been initiated and will lead to decisions by the Board of Directors which will be communicated on 16 December 2008. Board and Management sincerely regret this measure and would like to point out that the company will endeavour to fully assume its social responsibilities. Contact with public authorities on this issue has been established and a social plan will be presented in time.

Arpida will now thoroughly analyse the situation with external experts to determine the future development of Iclaprim. Basis for this analysis will be the full FDA response to the Iclaprim dossier and the publication of the phase II oral step down therapy trial.

"We were very surprised by this very clear negative ruling by the FDA advisory board", CEO Jurgen Raths said. "In particular we are very upset by the steps we are forced to take in regards to our staff. The advisory board's recommendation has come totally unexpected, because we are still convinced that Iclaprim offers a valuable therapeutic asset for the treatment of complicated skin and skin structure infections (cSSSI), especially where MRSA (resistant bacteria called methicillin-resistant staphylococcus aureus) are involved. We will use the FDA's feedback as well as furthe
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arpidas iclaprim MAA Accepted for Review by EMEA
2. Arpida Reports Interim Results for Six Months to 30 June 2008
3. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
6. Arpida Announces Conference Call on 17 April
7. Arpida Announces Agenda Items for Shareholders Meeting
8. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
9. Arpida Announces Full Year 2007 Financial Results
10. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
11. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 The University ... the Max Planck Society establishing the Max ... The center will link two of the world's foremost ... be only the third Max Planck Centre in North ... society for optics and photonics, was with university ...
(Date:5/26/2015)... WORMS, GERMANY – May 26, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACT™, an independent organization that certifies manufacturers, suppliers, ... All three Grace facilities that produce its SYLOID® ... have now received GMP certification, following the Curtis ...
(Date:5/26/2015)... REDWOOD CITY , Kalifornien und HILDEN, ... QIAGEN Clinical Insight ... Interpretation von Genvarianten und die Erstellung dazugehöriger ... und ESHG     QIAGEN N.V. ... QIA) gab heute die Markteinführung von QIAGEN ...
(Date:5/26/2015)... RICHMOND, Calif. , May 26, 2015  Sangamo BioSciences, ... Lanphier , Sangamo,s president and CEO, will provide an update ... programs and an overview of the company,s business strategy at ... 2015 Global Healthcare Conference. The conference is being held in ... presentation will be webcast live and may be accessed via ...
Breaking Biology Technology:Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... 16 /PRNewswire-Asia-FirstCall/ -- A-Power Energy,Generation Systems, Ltd. (Nasdaq: ... of distributed power generation ("DG") systems in China and ... signed a,contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. ... Province of,China. , Pursuant to ...
... SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company ... announce that additional results of its,recently completed international Phase III ... at the 2009 European Cystic Fibrosis,Conference in Brest, France. , ... conference on Friday 12 June by Dr Diana,Bilton of the ...
... Sharoky, M.D. to Assume the Role of Chairman of the ... Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical company, ... President, Chief Executive Officer and Chairman of the Board of ... Allan has served as Insmed,s President, Chief Executive Officer and ...
Cached Biology Technology:A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 2A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4Insmed CEO Resigns Due to Health Concerns 2Insmed CEO Resigns Due to Health Concerns 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... E supplements may blunt the improvement of muscular endurance ... new study published today [3 February] in The Journal ... widely used, understanding if they interfere with cellular and physiological ... health purposes as well as to athletes., Dr Gran Paulsen, ...
... Immune cells undergo ,spontaneous, changes on a daily basis ... diligent surveillance of our immune system, Melbourne scientists have ... Eliza Hall Institute found that the immune system was ... their early stages, before they developed into B-cell lymphomas ...
... In many people with autism and other neurodevelopmental disorders, ... other very well. Scientists have now identified, for the ... connectivity can come about. In a study published online ... European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, and ...
Cached Biology News:Vitamin C and E supplements hampers endurance training 2Red alert: Body kills 'spontaneous' blood cancers on a daily basis 2Making your brain social 2